Among the growing number of IDO1 catalytic inhibitors that exploit the structural flexibility of the IDO1 target (5), the potent and selective inhibitor epacadostat has reached the most advanced phase III clinical stage in metastatic melanoma patients to study the synergistic efficacy in combination with pembrolizumab. Here, IDO1 is linked to metastatic melanoma.